Mesoblast LtdOTC Pink - Current Information:MEOBF
- LAST PRICE0.6329
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0103/ 100
- Ask / Lots1.0500/ 1
- Open / Previous Close--- / 0.6329
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Sep 24, 2024
DJ Mesoblast Raised to Buy From Hold by Maxim Group, from 9:12AM ET on Tuesday Sep 24, 2024 by Dow Jones
9:12AM ET on Tuesday Sep 24, 2024 by Dow Jones
Aug 29, 2024
DJ Mesoblast Raised to Buy From Hold by Jefferies, from 11:37AM ET on Thursday Aug 29, 2024 by Dow Jones
11:37AM ET on Thursday Aug 29, 2024 by Dow Jones*DJ Mesoblast Upgraded to Buy from Hold by Jefferies, from 1:43AM ET on Thursday Aug 29, 2024 by Dow Jones
1:43AM ET on Thursday Aug 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mesoblast Ltd | 1.0B | --- | --- |
Company Information
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Contact Information
- Headquarters
- L 38 55 Collins StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
|---|---|
Revenue (TTM) | $8.6M |
Shares Outstanding | 1.1B |
Mesoblast Ltd does not pay a dividend. | |
Beta | 2.92 |
EPS | $-0.13 |
Book Value | $0.61 |
P/E Ratio | --- |
Price/Sales (TTM) | 119.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,173.11% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
